Latest Healthcare News

Page 6 of 197
Henry Schein has raised its 2026 adjusted earnings and EBITDA outlook after a quarter of stronger sales, led by US dental merchandise volumes. The result also included a tariff refund benefit, making the quality of earnings an important part of the story.
Ada Torres
Ada Torres
4 Nov 2026
DuPont delivered a stronger-than-expected third quarter, with adjusted EPS rising 62% and both operating segments expanding margins. The chemicals group has lifted its full-year outlook again while committing to another US$250 million share repurchase.
Victor Sage
Victor Sage
4 Nov 2026
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Healthpeak has raised its 2026 adjusted FFO and same-store NOI guidance after a quarter of strong senior housing growth, leasing activity and portfolio expansion. The uplift comes with a lower GAAP earnings outlook, reflecting depreciation from newly acquired senior housing assets.
Eva Park
Eva Park
3 Nov 2026
IDEXX Laboratories has raised its 2026 revenue and earnings outlook after reporting 10% third-quarter revenue growth and an 18% rise in diluted EPS. The upgrade came alongside rapid adoption of its inVue Dx analyzers, although acquisition costs prompted a lower full-year operating margin forecast.
Ada Torres
Ada Torres
2 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026
INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
Ada Torres
2 Nov 2026
ResMed has delivered a stronger first quarter for fiscal 2027, with revenue up 6% to US$1.415 billion and net income rising 20% to US$418 million. The headline result was helped by a preliminary gain on the MatrixCare sale, while the core Sleep and Breathing Health business continued to expand.
Ada Torres
Ada Torres
2 Nov 2026
LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.
Ada Torres
Ada Torres
30 Oct 2026
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
EZZ Life Science cut its quarterly operating cash outflow sharply despite a 37.7% drop in customer receipts, as weaker Chinese e-commerce sales continued to weigh. EAORON skincare growth and a $9.16 million cash balance offer some support, but distributor collections and potential product returns remain unresolved.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive